We are thrilled to announce that DreaMed, a pioneering force in diabetes management technology, has successfully raised $3 million in funding to advance our mission of improving the lives of those living with diabetes. Founded in 2014, DreaMed has made significant strides in the field, notably with the introduction of the world鈥檚 first artificial pancreas technology. Our proprietary decision-support tools, which utilize data from continuous glucose monitoring (CGM) and self-monitoring of blood glucose (SMBG) systems, have garnered FDA clearance, making us the first and only company to achieve this milestone. This latest funding will enable us to further develop our innovative solutions, enhancing our existing products while accelerating the launch of new, groundbreaking technologies.
At DreaMed, our founding team of physicians and engineers is deeply committed to translating real-world insights from leading diabetes specialists into effective management solutions. As such, we prioritize the highest standards of privacy, security, and regulatory compliance, operating under ISO 27001, GDPR, and HIPAA standards to protect our users. The funds raised will support our ongoing research and development efforts, allowing us to refine our technology and expand our capabilities in delivering personalized diabetes care. We believe that with the support of our investors, we can continue to revolutionize diabetes management, making a substantial impact on the health and well-being of individuals with diabetes around the globe. Stay tuned for exciting updates as we embark on this promising journey!
